Motor dysfunction and cognitive impairment are major symptoms in both Huntington’s Disease (HD) and Parkinson’s Disease (PD). A breakthrough in HD research was the identification of the gene that causes this devastating monogenetic illness. Similarly, several genes were found to cause familial forms of PD. With their identification, a plethora of genetic animal models has been generated and has revolutionized the understanding of the pathobiology and pathophysiology of these disorders. The models allow us to study the earliest manifestations of the diseases behaviorally and neuropathologically and help us understand how they progress over time. Additionally, neurotoxic animal models are still of high interest to the PD field, as they are being used to study e.g. mitochondrial dysfunction in PD. This book focuses on animal models of both diseases and how they have helped and will continue to help understand the behavioral neurobiology in these disorders.

Despite being described about 200 years ago, the pathophysiology of Parkinson’s disease (PD) is not well understood due to its complex etiology and heterogeneity of symptoms and progression. Animal models provide a great opportunity to follow the progression of neurodegeneration and to screen potent therapeutic molecules, knowledge of which can be critical for different levels of clinical trials. Contemporary health technologies are coming in handy to accelerate the pace of developing novel and refined therapeutic strategies for PD. This book, Parkinson’s Disease - Animal Models, Current Therapies and Clinical Trials, provides a comprehensive overview of PD, presenting information on animal models of PD and contemporary therapeutic strategies, health technologies, clinical trials, and their influence on the quality of life of patients with PD.